- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00916747
Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Genetic Diagnosis: All patients must have confirmatory mutational analysis showing mutation in the lamin A gene.
- Clinical Diagnosis: Patients must display clinical signs of progeria as per the clinical trial team.
- Travel: Patients must be willing and able to come to Boston for appropriate studies and examinations at initiation of study and at months 6, 12, 18 and 24 on study.
- Patient must have adequate organ and marrow function as defined by the following parameters:
- Blood: APC (ANC + bands + monocytes = APC) > 1,000/microliters, Platelets > 75,000/microliters (transfusion independent); Hemoglobin >9g/dl.
- Renal: creatinine Less than or equal 1.5 times normal for age or GFR > 70 ml/min/1.73m2.
- Hepatic: bilirubin Less than or equal to 1.5 x upper limit of normal for age; SGPT (ALT) < and SGOT (AST) < 5 x normal range for age.
- PT/PTT: PT/PTT < 120% upper limit of normal OR PI approval
- No overt renal, hepatic, pulmonary disease or immune dysfunction.
- 25-hydroxyvitamin D ≥ 20 ng/ml within 4 weeks of bisphosphonate infusion.
- Signed informed consent according to institutional guidelines must be obtained and patient must begin therapy within twenty eight (28) days.
Exclusion Criteria:
- Other than the drugs used in this protocol, drugs targeted to treat Progeria are excluded. Drugs to treat symptoms of Progeria are permitted.
- Patients must not be taking medications that significantly affect the metabolism of lonafarnib at the time they start lonafarnib
- Patient must have no uncontrolled infection.
- Subjects who have known or suspected hypersensitivity to any of the excipients included in the formulation should not be treated.
- Patients must not be pregnant or breast-feeding. Female patients of childbearing potential must have negative serum or urine pregnancy test. Male and female patients of reproductive potential must agree to use a medically accepted form of birth control while on study and up to 10 weeks after treatment. It is permissible for female patients to take oral contraceptives or other hormonal methods while receiving treatment with lonafarnib.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment arm
All patients will receive zoledronic acid, pravastatin and lonafarnib
|
Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus. Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period. Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the therapeutic effects of the combination of zoledronic acid, pravastatin and lonafarnib in patients with HGPS.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To describe any acute and chronic toxicities associated with treating progeria patients with the combination of zoledronic acid, pravastatin and lonafarnib.
Time Frame: 2 years
|
2 years
|
To investigate which clinical and laboratory studies are needed to monitor or alter therapy to prevent unacceptable toxicity.
Time Frame: 2 years
|
2 years
|
To assess the pharmacokinetics of lonafarnib in patients with progeria.
Time Frame: 2 years
|
2 years
|
To assay for the inhibition of HDJ-2 farnesylation in Peripheral Blood Leukocytes (PBL).
Time Frame: 2 years
|
2 years
|
To assay for changes in research-based potential markers of efficacy such as levels of prelamin A, mature lamin A, progerin, and HP1 in protein isolated from PBL.
Time Frame: 2 years
|
2 years
|
To assess changes in leptin levels, glucose utilization, skeletal abnormalities including bone mineral density and X-ray finding, joint contracture and function, and growth
Time Frame: 2 years
|
2 years
|
To assess changes in auditory function, dental anomalies, dermatologic changes including hair density, nutrition with calorie analysis and energy expenditure, body composition analysis by DXA scan, and cardiovascular structure and function.
Time Frame: 2 years
|
2 years
|
To compare and incorporate clinical and laboratory data obtain from this study with that obtained during the single agent lonafarnib trial as well as the pilot combination trial of zoledronic acid, pravastatin and lonafarnib
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Kieran, MD, PhD, Children's Hospital Boston/ Dana-Farber Cancer Instittue
Publications and helpful links
General Publications
- Gordon LB, Kleinman ME, Massaro J, D'Agostino RB Sr, Shappell H, Gerhard-Herman M, Smoot LB, Gordon CM, Cleveland RH, Nazarian A, Snyder BD, Ullrich NJ, Silvera VM, Liang MG, Quinn N, Miller DT, Huh SY, Dowton AA, Littlefield K, Greer MM, Kieran MW. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. Circulation. 2016 Jul 12;134(2):114-25. doi: 10.1161/CIRCULATIONAHA.116.022188.
- Gordon LB, Massaro J, D'Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW; Progeria Clinical Trials Collaborative. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation. 2014 Jul 1;130(1):27-34. doi: 10.1161/CIRCULATIONAHA.113.008285. Epub 2014 May 2.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Laminopathies
- Progeria
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Bone Density Conservation Agents
- Pravastatin
- Zoledronic Acid
- Lonafarnib
Other Study ID Numbers
- Progeria Efficacy
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Progeria
-
Bundang CHA HospitalCompletedHutchinson-Gilford Progeria SyndromeKorea, Republic of
-
Assistance Publique Hopitaux De MarseilleCompletedHutchinson-Gilford Progeria SyndromeFrance
-
PRG Science & Technology Co., Ltd.Amarex Clinical ResearchCompletedHutchinson-Gilford Progeria Syndrome | Werner SyndromeUnited States
-
Boston Children's HospitalEnrolling by invitation
-
Eiger BioPharmaceuticalsApproved for marketing
-
Boston Children's HospitalDana-Farber Cancer Institute; Brigham and Women's Hospital; Schering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
Monica E. KleinmanSchering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
National Human Genome Research Institute (NHGRI)Completed
-
Centre Hospitalier Universitaire DijonNot yet recruitingKosaki Overgrowth Syndrome | Penttinen SyndromeFrance
Clinical Trials on Lonafarnib, Zoledronic Acid, and Pravastatin
-
Assistance Publique Hopitaux De MarseilleCompletedHutchinson-Gilford Progeria SyndromeFrance
-
Boston Children's HospitalDana-Farber Cancer Institute; Brigham and Women's Hospital; Schering-PloughCompletedProgeria | Hutchinson-Gilford SyndromeUnited States
-
University of CalgaryRecruitingOsteo Arthritis Knee | Anterior Cruciate Ligament Injuries | Anterior Cruciate Ligament Rupture | Anterior Cruciate Ligament TearCanada
-
Yonsei UniversityRecruiting
-
Novartis PharmaceuticalsCompleted
-
Thomas J. SchnitzerNovartisTerminatedBone LossUnited States
-
University of CalgaryRecruitingOsteoporosis | Bone Loss | Osteopenia | Osteoporosis, PostmenopausalCanada
-
Columbia UniversityNovartis PharmaceuticalsCompletedLiver Transplantation | Heart Transplantation | Bone ResorptionUnited States
-
Toufiqe-E-EalahiRecruiting
-
Children's Hospital of Eastern OntarioWithdrawnAcute Lymphoblastic Leukemia | Osteoporosis | OsteonecrosisCanada